04 market and products

Page 1

Disclaimer

These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation relating to the Company. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those expressed in or implied by these forward-looking statements as a result of various factors, many of which are beyond the ability of DiaSorin S.p.A. to control or estimate precisely. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange. Luigi De Angelis, the Officer Responsible for the preparation of corporate financial reports of DiaSorin S.p.A., in accordance with the second subsection of art. 154-bis, part IV, title III, second paragraph, section V-bis, of Legislative Decree February 24, 1998, no. 58, declares that, to the best of his knowledge, the financial information included in the present document corresponds to book of accounts and book-keeping entries of the Company.Â


2015-2017 PLAN:

MARKET AND PRODUCTS


IVD Market: Immunodiagnostic and Molecular Diagnostic

In Vitro Diagnostic (IVD) Market Value: ~ 造 45 billion POINT OF CARE MICROBIOLOGY HAEMATOLOGY

7%

OTHER MOLECULAR DIAGNOSTIC

9% 12%

6% 6%

CLINICAL CHEMISTRY

18% 21% 21% SELF-MONITORING BLOOD GLUCOSE

IMMUNODIAGNOSTIC


IVD Market Immunodiagnostic Market

Molecular Diagnostic Market

Value: ~ 造 8.1 billion

Value: ~ 造 5.4 billion

ONCOLOGY AND ENDOCRINOLOGY

OTHER

26% DRUG MONITORING ALLERGY

18%

26% 25%

HEPATITIS AND RETROVIRUSES

3% 6%

AUTOIMMUNITY

15%

7%

GI STOOL TESTING

5%

7%

BONE&MINERAL

15%

CARDIAC MARKERS

Bone & Mineral

2015

INFECTIOUS DISEASE

2016

Molecular Diagnostic Pipeline 2017

Infectious Diseases

Bordetella G* Bordetella A* PCT II* HCV II

*Already available on the market

Qualitative Onco-Haematology

Campylobacter

H. Pylori IgG Endocrinology

AREA

2015

2016

PML-RAR 1-3

AML-ETO 1

PML-RAR 2

CBF D-E

2017

Sclerostin FGF-23

GI Stool Testing

INFECTIOUS DISEASES

13%

Immunodiagnostic Pipeline AREA

60%

ONCOLOGY

CBF A 6 to 8 Tests

6 to 8 Tests

Quantitative Onco-Haematology

BCR-ABL P210

BCR-ABL P190 + ABL

BCR-ABL ABL

PML-RAR 1 + ABL PML-RAR 2 + ABL PML-RAR 3 + ABL


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.